+

WO1997005170A2 - Anticorps a large specificite - Google Patents

Anticorps a large specificite Download PDF

Info

Publication number
WO1997005170A2
WO1997005170A2 PCT/GB1996/001889 GB9601889W WO9705170A2 WO 1997005170 A2 WO1997005170 A2 WO 1997005170A2 GB 9601889 W GB9601889 W GB 9601889W WO 9705170 A2 WO9705170 A2 WO 9705170A2
Authority
WO
WIPO (PCT)
Prior art keywords
generic
antibodies
compounds
enzyme
cells
Prior art date
Application number
PCT/GB1996/001889
Other languages
English (en)
Other versions
WO1997005170A3 (fr
Inventor
Michael Robert Anthony Morgan
Colin Malcolm Ward
Andrew Philip Wilkinson
Heather Avril Lee
Original Assignee
The Minister Of Agriculture Fisheries & Food In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Minister Of Agriculture Fisheries & Food In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland filed Critical The Minister Of Agriculture Fisheries & Food In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland
Priority to JP9507384A priority Critical patent/JPH11510691A/ja
Priority to EP96926469A priority patent/EP0842197A2/fr
Priority to CA002227599A priority patent/CA2227599A1/fr
Priority to AU66638/96A priority patent/AU6663896A/en
Publication of WO1997005170A2 publication Critical patent/WO1997005170A2/fr
Publication of WO1997005170A3 publication Critical patent/WO1997005170A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Definitions

  • the present invention relates to antibodies having a broad specificity.
  • the invention further relates to methods of raising such antibodies, and to processes and kits employing them.
  • antibodies which are able to specifically bind to several members of a class of related compounds.
  • Such antibodies have utility in areas of analysis of groups of compounds which exert similar activities by means of a particular binding ability e.g. drugs, pesticides, mycotoxins, agonists, antagonists, vitamins etc.
  • the antibodies can be used in screening assays to detect the presence of known or novel compounds having the particular binding ability, and also to extract the compounds (the immunoaffinity approach) .
  • WO 94/27149 discloses a strategy for raising antibodies which are specifically directed to bind two or more specified pesticidal compounds.
  • the disclosed method employs a hapten-protein conjugate having a particular phosphate nucleus; antibodies raised against the conjugate have binding ability for several organophosphates.
  • This methodology requires chemical synthesis of the hapten structure, and can not be readily extended to cover other groups of compounds e.g. veterinary drugs, which may have less structural similarity within the group.
  • a method for producing generic antibodies having a specific binding affinity for two or more of a class of compounds demonstrating a common mode of biological activity comprising selecting a receptor or enzyme through which the class of compounds exert the biological activity, raising intermediate monoclonal antibodies (iMABs) against the recognition site of the receptor or enzyme, inoculating an animal with these iMABs or fragments thereof and recovering the generic antibodies from a body fluid or tissue of the animal
  • the specific binding affinity is preferably such that the two or more compounds are bound with relative affinities in the range of 1 to IO 4 , more preferably between 1 and IO 3 , and ideally between 1 and IO 2 , as measured by standard binding assays.
  • the generic antibodies can be used to detect or extract the compounds from materials even when the compounds are present in widely varying proportions.
  • the generic antibodies detect at least four compounds from the class.
  • the receptor or enzyme through which the class of compounds exert the biological activity can be selected in accordance with information available in the art. This may one for which the compounds are a natural substrate or agonist, alternatively it may be one for which the compounds are an artificial substrate or antagonist, or an inhibitor.
  • the receptor or enzyme has a recognition site which is readily accessible to an antibody i.e. which is not concealed within a cleft.
  • the antibody could be raised against a peptide corresponding to the epitopic features of the recognition site.
  • the iMABs, or binding-site fragments thereof are themselves used as immunogens.
  • the immunogens can be in either unconjugated or conjugated (e.g. with BSA) form.
  • Antibodies raised against the binding site of the iMABs will themselves have a binding site which mimics the original enzyme or receptor.
  • these generic antibodies will have a specific binding affinity for the compounds of interest, and can be selected or isolated by immunoaffinity techniques using one or more of the compounds e.g. in immobilised form.
  • a method for producing cells capable of producing generic MABs capable of producing generic MABs (gMABs) having a specific binding affinity for two or more of a class of compounds demonstrating a common mode of biological activity comprising a method as described above but wherein, rather then recovering antibodies from a body fluid of the animal, antibody-producing cells are removed from the animal and are used to create hybridomas using methodology well known to those skilled in the art. Alternatively, the DNA from the antibody-producing cells is used to transfect other cells in which it can be expressed. The hybridomas or transfected cells can be selected by use of immunoaffinity techniques which detect the gMABs produced therefrom.
  • a method for producing gMABs having a specific binding affinity for two or more of a class compounds demonstrating a common mode of activity comprising culturing the cells produced as above and isolating gMABs from the culture medium.
  • the invention further makes available a method of screening a sample for the presence or absence of compounds demonstrating a common mode of activity comprising contacting the sample with generic antibodies produced as described above under conditions sufficient to permit the formation of immune complexes; detecting the formation of immune complexes; and relating the presence or absence of immune complexes to the presence or absence of the compounds.
  • the invention further makes available a method for extracting compounds demonstrating a common mode of activity from a sample comprising a screening method as claimed above wherein any immune complexes formed are treated such as to dissociate the compounds therefrom e.g. using acetone.
  • kits for use in the methods above comprising one or more of the materials (i.e the generic polysera, the generic antibodies, or the cell lines) described above.
  • the kits comprise gMABs plus means for detecting the formation of immune complexes such as are well known to those skilled in the art e.g. ELISA.
  • Detection may take the form of a displacement assay wherein the presence of compounds displaces a labelled marker (e.g. the immunogen used to raise the antibody, or a labelled compound of the type bound by the antibody) from the generic antibody binding site. The displacement of this marker can then be related tc the presence of the compounds.
  • a labelled marker e.g. the immunogen used to raise the antibody, or a labelled compound of the type bound by the antibody
  • Kits could take the form of dip-sticks or card assays such as can be devised by the skilled addressee in the light of the present disclosure without undue burden.
  • Organophosphates all contain a central P(S) or P(O) entity and are employed as pesticides and nerve-agents. Many exert their properties via interaction with the active site of hydrolases e.g. acetylcholinesterase, serine proteases, parathion hydrolase and cutinase, thus the active site constitutes a recognition site for these compounds.
  • hydrolases e.g. acetylcholinesterase, serine proteases, parathion hydrolase and cutinase
  • enzymes having a recognition site could themselves be used for organophosphate screening, enzymes have the disadvantages that they are generally less robust, more expensive, and less able to be manipulated then MABs. These enzymes are, however, candidates for use in raising the iMABs employed in the present invention.
  • Organophosphates are frequently employed as pesticides on food crops, common agents being chlorpyrifos, malathion, chlorfenvinphos and tetrachlorfenvinphos. It is important to test foodstuffs derived from treated plants for organophosphate residues to ensure that they do not breach legal requirements.
  • a test based around the generic MABs of the present invention provides an innovative, robust, cheap and rapid solution to the problem of mass screening of food samples for the presence of pesticide residues, and would enable rapid elimination of negative samples from surveillance programs. Positive samples could be further tested to establish the precise nature of the contaminants present.
  • the invention makes available a method of screening a sample for organophosphate compounds comprising a method of screening a sample as described above wherein the iMABs are raised against an enzyme or receptor which binds or is inhibited by organophosphates e.g. a serine protease, but most preferably cutinase.
  • organophosphates e.g. a serine protease, but most preferably cutinase.
  • the method may be limited to either P(O) or P(S) based organophosphates.
  • the original enzyme or receptor is selected such as to generate generic antibodies having an affinity for both types of organophosphate.
  • the sample to be screened is a food item.
  • the screening method could also be used for the purpose of screening samples for novel compounds having organophosphate type activities e.g. screening environmental samples for new lead compounds for use as pesticides.
  • the invention makes available methods, materials and kits with utility in the field of screening for, or extracting, compounds demonstrating a common mode of activity.
  • gMABs to bind a wide variety of human or veterinary drugs.
  • ⁇ -lactam antibiotics which can be detected using antibodies based around the ⁇ -lactamase active site.
  • Fig 1 shows displacement of gMAB 1507 from an immobilised pesticide conjugate by four different pesticides.
  • EXAMPLE 1 A GENERIC MAB HAVING SPECIFIC BINDING AFFINITY FOR ORGANOPHOSPHATE PESTICIDES
  • mice or rabbits were injected subcutaneously on the back with immunogen dispersed in saline:Freunds adjuvant (1:1, v:v) . Incomplete Freunds adjuvant was used, except for the first injection of each animal where complete Freunds adjuvant was substituted. Rabbits were bled twice from the marginal ear vein, and mice were bled once from the tail, 10-14 days after injection.
  • Murine MABs were raised to cutinase using the methods described by Galfr and Milstein (1981) Methods in Enzymology 73, 3-46.
  • Spleenocytes were removed from the mouse 4 days after immunisation and fused with myeloma cells in a ratio of between 3:1 and 10:1 respectively in the presence of polyethylene glycol. After 10 days fusion plates were screened by ELISA and positive binding wells expanded for rescreening. Suitable cell lines were cloned 3 times by the limiting dilution method, and wells producing antibody identified by ELISA. The MABs were then grown up in quantity in flasks, in Optimem medium containing 1-4% foetal calf serum (FCS) .
  • FCS foetal calf serum
  • MABs were purified from culture supernatant by initial concentration using a Minitan concentrator fitted with 30 kDa cut ⁇ off membranes (Millipore Ltd, Watford, U.K.). This process reduced the volume from 11 to 60 ml. The solution was then taken to 60% saturation at 4'C with ammonium sulphate and the protein pelleted by centrifugation at 10,000 rpm for 30 mins at 4'C. The protein was resuspended in double glass-distilled deionized water and then buffer-exchanged into 1.5 M-glycine/NaOH, pH 8.9, containing 3M-NaCl using Sephadex PD10 column (Pharmacia Ltd, Milton Keynes, U.K.). Antibodies were purified by affinity chromatography using a Protein A-FPLC column (Pharmacia Ltd) dialysed against 10 mM-ammonium hydrogen carbonate, and then freeze dried.
  • GENERAL CUTINASE ASSAY The assay for cutinase activity described by Kolattukudy et al (1981) Methods in Enzymology 71, 652-664 using p-nitrophenylbutyrate as substrate was adapted for microtitration plates. The substrate was prepared as described except that the solution was clarified using an ultrasonic bath.
  • the basic assay was as follows: 100 ⁇ l of 0.1 M-phosphate- buffered saline, pH 7.4, containing 0.05% (v/v) Tween 20 (PBST) was added to 50 ⁇ l/well of cutinase (40 ng ml "1 in PBST) in the appropriate wells of a microtitration plate, followed by 50 ⁇ l (50 ⁇ M) of p-nitrophenylbutyrate. The rate of increase in absorbance at 410 nm due to the formation of p-nitrophenol at room temperature was measured every 15 seconds for 7.5 mins using a Dynatech MR5000 plate reader (Dynatech Laboratories Ltd, Billinghurst, U.K.).
  • Control reactions measuring substrate autohydrolysis were included on the icrotitratrion plate by replacing the enzyme in these wells with an equivalent volume of buffer. Reaction progress curves were depicted for each microtitration plate well using the RMS programme supplied with the MR5000 plate reader. Initial velocities of the enzymic reactions were calculated by linear regression.
  • iMABs IFRN 1901-1906 The antibodies from these cell lines, designated iMABs IFRN 1901-1906, were all shown to be of the IgGl isotype and were purified by Protein A affinity chromatography. Differences were seen in the degree by which cutinase activity could be inhibited by purified antibodies.
  • iMABs 1901, 1902, 1904 and 1905 (40 ng) inhibited cutinase activity by 80 to 90%.
  • iMABs 1903 and 1906 inhibited the enzyme 58 and 30% respectively.
  • substrate concentration was varied from 50-500 ⁇ M and antibody concentration from 0-40ng.
  • Assays were as described above except that the assay temperature was maintained at 25 * C. Data was analysed by the method of Wilkinson (1961) Biochem J. 80, 324- 332.
  • Cutinase (1 mg) was incubated with chlorfenvinphos and methyl paraoxon (1.8 and 1.1 mM respectively) at room temperature in PBST. Samples were desalted on a Sephadex PD-10 column equilibrated with PBST. These samples together with uninhibited cutinase were used to coat sections of the same microtitration plates at lg ml '1 in 0.05M-carbonate/bicarbonate buffer, pH 9.6. Purified MABs diluted PBST (1-1000 ng ml "1 ) and added to the microtitration plates which were then incubated at 37 * C for 2 hrs.
  • HRP horseradish peroxidase
  • iMABs 1901-1906 bind at, or close to, the active site of cutinase, and that these antibodies can act as pesticide mimics and be used to generate gMABs that would bind to a broad spectrum of organophosphate pesticides.
  • iMAB ml-1 Enzyme (OD450 Chlorfenvinphos Methyl paraoxon concentration nm) alone inhibited inhibited
  • the binding of the antibodies to denatured cutinase was examined by SDS electrophoresis and protein transfer to nitrocellulose membranes. If the antibodies recognised discontinuous epitopes of the enzyme folded in its native state, then they should not bind to the denatured enzyme.
  • Purified anti-cutinase MABs were screened for binding to reduced- denatured cutinase by electrophoretic techniques. Cutinase was boiled for 15 minutes with 25% (w/v) sodium dodecyl sulphate (SDS) in Tris/HCl buffer (pH 8.0) . The reduced samples were then separated by electrophoresis using a Pharmacia Phast Gel Electrophoresis System (Pharmacia Ltd, St. Albans, U.K.) and SDS- polyacrylamide gels. Subsequently protein in the SDS gel was transferred to nitrocellulose membranes (Sartorius Ltd,Epsom,U.K) again using the Phast Gel System.
  • SDS sodium dodecyl sulphate
  • alkaline phosphatase substrate consisting of 5-bromo-4-chloro-3-inodolyl phosphate, magnesium chloride and nitrobluetetrazolium in ethanolamine buffer, pH 9.8.
  • alkaline phosphatase substrate consisting of 5-bromo-4-chloro-3-inodolyl phosphate, magnesium chloride and nitrobluetetrazolium in ethanolamine buffer, pH 9.8.
  • This substrate mixture gives a coloured precipitate following reaction on the nitrocellulose membrane at the region where the anti-mouse enzyme conjugate has bound.
  • MAGNETIC BEAD CONJUGATES The hydroxyl groups of polysaccharide coated magnetic beads (Dynal, New Ferry, U.K.) were activated using 2-fluoro-1-methyl pyridinium toluene-4-sulphonate (FMP) .
  • FMP 2-fluoro-1-methyl pyridinium toluene-4-sulphonate
  • iMAB 1904 in sodium hydrogen carbonate (0.2M) was mixed with activated magnetic beads from the supernatant which was stored frozen. Beads were resuspended in 0.1 M, pH 8.0 Tris/HCl buffer to block any remaining FMP-activated hydroxyl groups. Beads were then extensively washed with 20 mM, pH 7.4 phosphate buffer containing 0.5M NaCl (PBS) and stored frozen. The effectiveness of the conjugation was assessed by testing the stored supernatant for inhibition of cutinase activity. This test was negative, indicating complete conjugation of antibody to beads.
  • PROTEIN CONJUGATES iMABs 1903, 1905 and 1906 were conjugated to bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH) using 1.0% (v/v) glutaraldehyde in PBS.
  • BSA bovine serum albumin
  • KLH keyhole limpet haemocyanin
  • a bifunctional photoactivatable compound, p-azidobenzoyl hydrazide Pierce Ltd, Chester, U.K.
  • conjugated antibody was separated from unconjugated material using Sephadex G200. Conjugated antibody was shown to be active using the cutinase inhibition assay.
  • TPB trans-4-phosphono-2-butenic acid diethyl ester
  • Mouse tail bleeds were serially diluted 1:100, 1:500 and 1:1000
  • Polyclonal sera were also tested for the ability of a mixture of pesticides (chlorpyriphos, chlorfenvinphos, carbophenothion and ethyl paraoxon; Promochem, Welwyn Garden City, U.K.) to inhibit antisera binding to microtitration plates coated with TPB-BTG.
  • pesticides chlorpyriphos, chlorfenvinphos, carbophenothion and ethyl paraoxon; Promochem, Welwyn Garden City, U.K.
  • the pesticides were mixed in equal amounts to give a total concentration range of 45 ng to 45 g ml-1.
  • the pesticide solutions were added to microtitration plates coated with TPB-BTG and the assay continued as described above.
  • Hybridomas growing in the wells of microtitration fusion plates were screened for the production of generic antibodies which could bind to TPB-BTG and CPT-B-lactoglobulin and for inhibition of this binding by the pesticides carbophenothion, chlorfenvinphos and ethyl paraoxon.
  • Carbophenothion and chlorfenvinphos were conjugated to B-lactoblobulin as follows. Thiol groups were introduced onto B-lactoglobulin by reacting this protein with s- acetylmercaptosuccinic anhydride.
  • Thiolated protein was then conjugated to each pesticide via displacement reaction between the chlorine groups of the pesticide and the thiol groups of the protein by mixing in 0.1 M, pH 8.0 phosphate buffer at room temperature for 12 hrs.
  • Supematants from the cells were transferred, using a Biomek 1000 Automated laboratory Workstation (Beckman Ltd, High Wycombe, U.K.) in duplicate to wells of a microtitration plate coated with the pesticide conjugates.
  • One set of wells contained PBST only (in order to assess binding to the pesticide conjugate) and one set contained pesticide mixture (45 ⁇ g ml-1) (in order to assess inhibition of binding) .
  • the assay was carried out as described above.
  • gMAB 1507 for inhibition of binding to an immobilised pesticide-conjugate by pesticides in solution the culture supernatant containing the MAB was diluted 5-fold.
  • the pesticides tested are shown in Table 4.
  • Four pesticides demonstrated displacement of antibody in the assay and the standard curves over the range 5 pg - 5 g/well are shown in Fig. 1.
  • Demeton-S-methyl displaces at 5 ⁇ g/well and tetrachlorfenvinphos at 5 ⁇ g/well, however, displacement was greatest for ethyl paraoxon and chlorfenvinphos with a sensitivity in each case of 500 pg/well.
  • the results were similar whichever pesticide conjugate was used on the plate. Further experiments were conducted to show that gMAB 1507 demonstrated the expected characteristics.
  • Pesticide Least amount of pesticide to give significant inhibition (well '1 )
  • pesticides were also tested but showed no inhibition of binding: azamethiphos, edifenphos, propetamphos, phenthoate, menvinphos, methamidiphos, sulfotep, dichrotophos, valmidothion, fosamine ammonium, fenamiphos, monocrotophos, cyanofenphos, dichlorvos, malathion, parathion ethyl.
  • gMAB 1507 should also be displaced from binding to immobilised pesticide with iMAB 1901.
  • Table 5 shows the result of a chequerboard ELISA where iMAB 1901 and gMAB 1507 were added together at differing dilutions onto a CPT-B-lactoglobulin coated plate.
  • the percent binding of gMAB 1507 in the presence of increasing concentrations of iMAB 1901 compared to the binding of gMAB 1507 alone show that it is prevented from binding to the pesticide by iMAB 1901. It was also shown that other cutinase-inhibiting iMABs could displace gMAB 1507, but to a lesser extent.
  • Table 5 Displacement of gMAB 1507 by iMAB 1901 from a CPT-B- lactoglobulin plate
  • Affinity columns in which - gMAB 1507 was covalently linked to a solid phase support were prepared by two methods.
  • Protein A-Agarose Immunopure Protein A (1 ml, Pierce) was washed in Tris buffer and allowed to react with 11 mg of purified MAB. Unbound sites were deactivated with triethanolamine.
  • Protein A has a strong affinity for mouse IgG there is no covalent link between them and the MAB can be disassociated, for instance with high pH or high salt concentration. To avoid this, the Protein A and IgG were cross linked by reaction with 15 mM pimelidate followed by ethanolamine to block unreacted sites and washing in borate buffer.
  • CNBr-Sepharose CNBr-activated Sepharose (0.3g, Pharmacia) was allowed to swell and repeatedly washed on a scintered funnel with dilute HCl before washing in carbonate buffer. The gel was reacted with 11 mg of purified MAB on a rotating wheel for 2 hrs and subsequently washed with carbonate buffer. After standing ovemight in Tris buffer the gel was washed 5 times alternately with acetate and Tris buffers of pH 4.0 and 8.0 respectively.
  • the MAB-conjugated gels were stored in phosphate-biffered saline (PBS) at 4"C until required.
  • PBS phosphate-biffered saline
  • the columns were prepared by filling a 1 ml syringe with 0.2 ml of one of the gels, and washing with 3 x 5 ml PBS.
  • the sample is prepared in 1 ml PBS and applied to a column.
  • the column is washed with PBS (3ml) followed by 2 x 1 ml of acetone to elute any bound pesticide, before being re- equilibrated in PBS.
  • the eluted pesticide is then extracted using 3 x 1 ml of hexane and analysed by HPLC.
  • a kit for testing for the presence of organophosphates particularly chlorpyrifos, chlorfenvinphos, tetrachlorfenvinphos, ethyl paraoxon, demeton-S-methyl and CPT was provided as follows:
  • iMAB 1901 was conjugated to HRP by the periodate method.
  • HRP (lOmg) dissolved in distilled water (2.5 ml) was reacted with 0.1 M sodium periodate (0.5 ml) stirring for 1.5 hrs at room temperature. The mixture was dialysed against 1 mM sodium acetate pH 4.4 over 18 hrs.
  • Purified MAB (2 mg) was dissolved in 0.25 M carbonate buffer (2ml) pH 9.4. added to the dialysate and stirred for 4h at room temperature in the dark.
  • Sodium borohydride (0.2 ml of a 4 mg/ml solution) was added and allowed to stand at 4C overnight.
  • the labelled antibody was dialysed against 3 X 11 of PBS, concentrated to 1 ml on an Amicon filter, sterilized through a 22 syringe filter, and the volume made up to 10 ml with a preservative solution containing bovine serum albumin (BSA) and thiomersal, before being stored at 4 * C.
  • BSA bovine serum albumin
  • immobilised gMAB 1507 is exposed to HRP-labelled iMAB 1901 in the presence of a sample suspected of containing organophosphate pesticides.
  • the presence of the pesticides is deduced by measurement of the amount HRP-labelled iMAB 1901 being displaced from gMAB 1507, the HRP activity being tested as in 6) .
  • An alternative kit was provided using the pesticide-coated plates described in 12), gMAB 1507 and the anti-mouse IgG-alkaline phosphatase conjugate of 7) . Binding of gMAB 1507 to the plate in the presence and absence of the sample was assessed using the conjugate as described in 7) , binding being reduced in the presence of pesticide.
  • the immunisation protocol and preparation of iMABs was as in the 1 st example.
  • Cell lines were screened as follows: from an initial 120 seeded fusion plate wells, 6 were selected which were shown to contain hybridomas secreting antibody that both bound to a ⁇ - lactamase coated plate and were displaced from this plate by lmg/ml penicillin G. Subsequent cloning of these hybridomas produced 6 stable cell lines.
  • the antibodies from these cell lines were checked to ensure that they were true inhibitors of fi- lactamase as follows: the effect of 100 ⁇ l supernatant was assessed on an activity assay based on l ⁇ g nitrocefin and 22 mU penicillinase in a final volume of 300 ⁇ l. Results are showed between 14 and 57% inhibition, strongly suggesting that one or more of the antibodies interact with the active cite of the enzyme.
  • Such antibodies may thus be used, in methods analogous to those in Example 1, as immunogens to produce generic antibodies for use in drug screening.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention se rapporte à un procédé permettant de fabriquer des anticorps génériques, à large spécificité, ayant une affinité de liaison spécifique pour deux ou plusieurs composés d'une classe de composés présentant un mode commun d'activité biologique (par exemple les pesticides à organophosphates). Ce procédé permet aussi de sélectionner un récepteur ou un enzyme par lequel la classe de composés exerce son activité biologique, de développer des anticorps monoclonaux intermédiaires (AMI) contre le site de reconnaissance du récepteur ou de l'enzyme, d'inoculer à un animal ces AMI ou leurs fragments, et de récupérer les anticorps génériques à partir d'un liquide organique ou d'un tissu de cet animal. Cette invention porte également sur les polysérums génériques, sur les anticorps génériques et les lignées cellulaires qui permettent de les produire, ainsi que sur les procédés et les matériels permettant de cribler un échantillon pour détecter la présence ou l'absence de composés qui présentent un mode commun d'activité en utilisant des anticorps génériques.
PCT/GB1996/001889 1995-08-02 1996-08-01 Anticorps a large specificite WO1997005170A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP9507384A JPH11510691A (ja) 1995-08-02 1996-08-01 広い特異性の抗体
EP96926469A EP0842197A2 (fr) 1995-08-02 1996-08-01 Anticorps a large specificite
CA002227599A CA2227599A1 (fr) 1995-08-02 1996-08-01 Anticorps a large specificite
AU66638/96A AU6663896A (en) 1995-08-02 1996-08-01 Broad specificity antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9515850.7A GB9515850D0 (en) 1995-08-02 1995-08-02 Broad specificity antibodies
GB9515850.7 1995-08-02

Publications (2)

Publication Number Publication Date
WO1997005170A2 true WO1997005170A2 (fr) 1997-02-13
WO1997005170A3 WO1997005170A3 (fr) 1997-03-13

Family

ID=10778655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/001889 WO1997005170A2 (fr) 1995-08-02 1996-08-01 Anticorps a large specificite

Country Status (6)

Country Link
EP (1) EP0842197A2 (fr)
JP (1) JPH11510691A (fr)
AU (1) AU6663896A (fr)
CA (1) CA2227599A1 (fr)
GB (1) GB9515850D0 (fr)
WO (1) WO1997005170A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
CN113049812A (zh) * 2021-03-26 2021-06-29 信达安检测技术(天津)有限公司 一种检测克百威的elisa方法及其试剂盒

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000472A1 (fr) * 1986-07-23 1988-01-28 Aphton Corporation Immunogenes et procedes ameliores de production d'immunogenes
WO1993017030A1 (fr) * 1992-02-27 1993-09-02 The Horticulture And Food Research Institute Of New Zealand Limited Detection immunologique d'organophosphates
GB9310238D0 (en) * 1993-05-18 1993-07-14 Mini Agriculture & Fisheries Method,agents and kits for detection of organic agents

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US7592439B2 (en) 1998-06-12 2009-09-22 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
CN113049812A (zh) * 2021-03-26 2021-06-29 信达安检测技术(天津)有限公司 一种检测克百威的elisa方法及其试剂盒
CN113049812B (zh) * 2021-03-26 2024-03-19 信达安检测技术(天津)有限公司 一种检测克百威的elisa方法及其试剂盒

Also Published As

Publication number Publication date
GB9515850D0 (en) 1995-10-04
AU6663896A (en) 1997-02-26
CA2227599A1 (fr) 1997-02-13
JPH11510691A (ja) 1999-09-21
WO1997005170A3 (fr) 1997-03-13
EP0842197A2 (fr) 1998-05-20

Similar Documents

Publication Publication Date Title
US5654178A (en) Immunoassay for tetrachloroisophthalonitrile (chlorothalonil), its derivatives and breakdown products
CA2047717C (fr) Anticorps monoclonaux contre de petites molecules et methodes pour les preparer
Friguet et al. Some monoclonal antibodies raised with a native protein bind preferentially to the denatured antigen
EP0205198A1 (fr) Complexe immunologique, sa préparation et son utilisation
US5807695A (en) Metallic cation binding polypeptides and methods therefor
US4957859A (en) Antibodies for transforming ras protein
Lewis et al. Conformation-specific monoclonal antibodies directed against the calcium-stabilized structure of human prothrombin
Serrar et al. The development of a monoclonal antibody-based ELISA for the determination of histamine in food: application to fishery products and comparison with the HPLC assay
Huot et al. Protection against nerve toxicity by monoclonal antibodies to the sodium channel blocker tetrodotoxin.
WO2002027322A2 (fr) Reactifs, methode et trousse permettant de detecter les proteines phosphinothricine-n-acetyltransferases
EP0142345A2 (fr) Vaccin anti-idiotypique à base d'anticorps monoclonaux anti-idiotypiques
US6111079A (en) Lead binding polypeptides and nucleotides coding therefore
Hirsch et al. Autoimmunity induced by HgCl2 in Brown-Norway rats. I. Production of monoclonal antibodies.
Homan et al. Monoclonal antibodies directed against the sexual binding site of Chlamydomonas eugametos gametes.
US5053492A (en) Immunopurification using monoclonal antibodies to Mojave toxin
WO1997005170A2 (fr) Anticorps a large specificite
Fathman et al. Genetic control of the immune response to nuclease: II. Detection of idiotypic determinants by the inhibition of antibody-mediated nuclease inactivation
AU636534B2 (en) Monoclonal antibodies for measuring okadaic acid
US5332665A (en) Species specific, high affinity monoclonal antibodies
US5972656A (en) Mercury binding polypeptides and nucleotides coding therefore
Chao et al. Characterization of monoclonal and polyclonal antibodies to human tissue kallikrein.
US5665559A (en) Production of monoclonal antibodies to bacteroides gingivalis by hybridoma BGII, VF9/2D
Jones et al. Monoclonal antibodies specific for the organophosphate pesticide azinphos‐methyl
Jones et al. Production of anti‐idiotypic monoclonal antibodies that mimic the phytotoxin dothistromin
Manabe et al. Monoclonal antibodies against the mercaptoethanol-sensitive structure of a cell-cell adhesion protein of Polysphondylium pallidum

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IS JP KE KG KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IS JP KE KG KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996926469

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2227599

Country of ref document: CA

Ref country code: CA

Ref document number: 2227599

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1997 507384

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1996926469

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996926469

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载